ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial (Q34522758)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial |
scientific article |
Statements
1 reference
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial (English)
1 reference
Malcolm Ranson
1 reference
Lisa A Hammond
1 reference
David Ferry
1 reference
Andrew Tullo
1 reference
Vince Miller
1 reference
Steve Averbuch
1 reference
Judy Ochs
1 reference
Charles Morris
1 reference
Andrea Feyereislova
1 reference
Helen Swaisland
1 reference
Eric K Rowinsky
1 reference
1 May 2002
1 reference
1 reference
20
1 reference
9
1 reference
2240-2250
1 reference
Identifiers
1 reference
1 reference